Last reviewed · How we verify
Epadel, Eicosapentaenoic acid
At a glance
| Generic name | Epadel, Eicosapentaenoic acid |
|---|---|
| Sponsor | Osaka General Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion (PHASE2)
- Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body (PHASE1, PHASE2)
- The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism (NA)
- EPA for Metastasis Trial 2 (PHASE3)
- Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (PHASE4)
- CreNeuroS™️CNS Fish Oil Plus Softgels Compared to Vascepa® Capsules and Deplin® Capsules in a Pharmacokinetic, Single Dose Evaluation on Healthy Adult Human Subjects Under Fasting Conditions (NA)
- Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk Cardiovascular Disease. (NA)
- Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epadel, Eicosapentaenoic acid CI brief — competitive landscape report
- Epadel, Eicosapentaenoic acid updates RSS · CI watch RSS
- Osaka General Medical Center portfolio CI